Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2010

PPD Inks Deal with HIHT University to Increase Network in Northern India

  • PPD and Himalayan Institute and Hospital Trust (HIHT University) agreed to create an investigator site to expand PPD’s network of investigators in northern India. The agreement will provide biopharmaceutical companies with access to large patient populations and researchers who can manage clinical trials in accordance with ICH/GCP guidelines.

    Under the agreement, PPD will develop the site by providing infrastructure support and exclusive training for site staff. Clinical trials in India are expected to grow at 25–30% annually, according to PricewaterhouseCoopers. PPD’s current presence in India includes offices in Bangalore, Mumbai, and New Delhi. It reportedly has more than 1,400 employees throughout Asia Pacific.

    HIHT University has a 750-bed multi-specialty tertiary care hospital that offers both undergraduate and postgraduate courses in medicine. The outpatient department treats approximately 1,500 patients daily with an average patient occupancy of 86% percent and is reportedly the largest postgraduate institute in the northern state of Uttarakhand.

    “The collaboration between PPD and HIHT will help bring more global clinical research into this region,” remarks Simon Britton, PPD’s vp of clinical development for Asia Pacific. “Our faculty will have an opportunity to participate in cutting-edge global research, and patients will benefit by having access to the latest available therapies.”

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »